Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE

Jazz Pharmaceuticals to Buy Azur Pharma

By Pharmaceutical Processing | September 20, 2011

PALO ALTO, Calif. (AP) — Jazz Pharmaceuticals Inc. is buying privately held Azur Pharma Ltd. in an all-stock deal that will create a specialty pharmaceutical company incorporated in Ireland.

Shareholders of Jazz will own nearly 80 percent of the company, to be renamed Jazz Pharmaceuticals plc. Jazz said its chairman and CEO Bruce Cozadd will keep those titles, while the Azur Pharma chairman and CEO will join the Jazz board.

The combined company is expected to have revenue of more than $475 million in its first year, Jazz said. It will have no debt and about $250 million in cash at closing.

In the U.S. Azur Pharma sells 10 drugs for the central nervous system and women’s health. It expects sales of $95 million to $100 million this year.

The deal needs antitrust approval in the U.S. Jazz said affiliates that hold 43 percent of its stock and holders of 99 percent of Azur Pharma shares support the deal. It is expected to close in the first quarter of next year.

Jazz makes Xyrem for narcolepsy patients and Luvox CR to treat obsessive compulsive disorder. Last year, it earned $32.8 million on sales of $173.8 million.

Jazz shares rose 85 cents, or 2 percent, to close at $43.74.

 

 

Related Articles Read More >

This is the logo of Hikma.
Hikma to spend another $1B on US manufacturing, R&D
Sandoz Logo 2025
Sandoz breaks ground on biosimilar plant in Slovenia
Nymi Logo_2022 (1)
Nymi, Caliber partner on passwordless authentication for pharma manufacturing
Building a resilient pharma supply chain
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE